ABSTRACT
OBJECTIVE To evaluate platinum content in biodegradable carboplatin-impregnated beads and retrospectively assess tolerability and outcome data for dogs treated by intralesional placement of such beads following surgical excision of subcutaneous sarcomas. DESIGN Evaluation study and retrospective case series. SAMPLE 9 carboplatin-impregnated beads and 29 client-owned dogs. PROCEDURES Platinum content in 9 carboplatin-impregnated beads from 3 lots was measured by spectrophotometry, and calculated carboplatin content was compared with the labeled content. Medical records were searched to identify dogs with subcutaneous sarcomas for which treatment included placement of carboplatin-impregnated beads between 2011 and 2014. Signalment, tumor characteristics, surgical and histologic data, adverse events, and local recurrences were recorded. Associations between variables of interest and adverse events or local disease-free interval were analyzed. RESULTS In vitro analysis identified a mean ± SD platinum content of 5.38 ± 0.97 mg/bead. Calculated carboplatin content (10.24 ± 1.84 mg/bead) was significantly greater than the labeled amount (4.6 mg/bead). Bead weight and total platinum content differed significantly among lots, but platinum content per bead weight did not. Mild-to-moderate local adverse events were reported for 11 of 29 tumors; all resolved without additional surgery. No dogs had signs of systemic toxicosis. Overall local disease-free rates 1, 2, and 3 years after surgery were 70%, 70%, and 58%, respectively, as determined by Kaplan-Meier analysis. CONCLUSIONS AND CLINICAL RELEVANCE Carboplatin-impregnated beads were well tolerated; however, results of in vitro tests indicated that caution is needed because of manufacturing inconsistencies.
Subject(s)
Antineoplastic Agents/therapeutic use , Carboplatin/therapeutic use , Dog Diseases/drug therapy , Neoplasm Recurrence, Local/veterinary , Sarcoma/veterinary , Soft Tissue Neoplasms/veterinary , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/analysis , Carboplatin/administration & dosage , Carboplatin/analysis , Combined Modality Therapy , Disease-Free Survival , Dog Diseases/mortality , Dog Diseases/surgery , Dogs , Drug Implants/administration & dosage , Drug Implants/analysis , Drug Implants/therapeutic use , Female , Male , Neoplasm Recurrence, Local/drug therapy , New Jersey , Retrospective Studies , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Treatment OutcomeABSTRACT
OBJECTIVE: To describe a case of hemoperitonium in a dog with Bartonellosis and peliosis hepatis (PH) lesions that resolved following antimicrobial therapy. CASE SUMMARY: A 3-year-11-month-old 22.5 kg female spayed mixed breed dog presented for progressive lethargy and vomiting. An abdominal ultrasonographic examination revealed moderate ascites, which when sampled was nonclotting hemorrhagic fluid. An exploratory laparotomy revealed a large volume of nonclotted blood in the dog's abdomen and blood-filled vesicular lesions dispersed diffusely along multiple lobes of the liver. Biopsies revealed lesions indicative of PH. Serology testing for Bartonella species was positive. Treatment with azithromycin resulted in Bartonella serology negative status and no further evidence of hemoperitonium at recheck examination 12 months after initial presentation. NEW OR UNIQUE INFORMATION PROVIDED: This is the first reported case of PH and hemoperitoneum in a Bartonella species serology positive dog wherein treatment with azithromycin resulted in serology negative status. There have been no subsequent episodes of hemoperitoneum in the 12 months since treatment.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Bartonella Infections/veterinary , Dog Diseases/diagnosis , Hemoperitoneum/veterinary , Peliosis Hepatis/veterinary , Animals , Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Bartonella Infections/diagnosis , Diagnosis, Differential , Dog Diseases/drug therapy , Dog Diseases/surgery , Dogs , Female , Hemoperitoneum/diagnosis , Peliosis Hepatis/diagnosisSubject(s)
Cat Diseases/diagnostic imaging , Tracheal Stenosis/veterinary , Animals , Cats , Dyspnea/etiology , Dyspnea/veterinary , Fatal Outcome , Male , Radiography , Thoracic Vertebrae/diagnostic imaging , Thoracic Vertebrae/pathology , Trachea/injuries , Tracheal Stenosis/diagnostic imaging , Tracheal Stenosis/pathologySubject(s)
Dog Diseases/diagnosis , Lumbar Vertebrae , Spondylitis/veterinary , Thoracic Vertebrae , Animals , Dog Diseases/diagnostic imaging , Dog Diseases/microbiology , Dogs , Euthanasia, Animal , Exophiala/isolation & purification , Female , Immunocompromised Host , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/pathology , Mycoses/microbiology , Mycoses/veterinary , Opportunistic Infections/microbiology , Opportunistic Infections/veterinary , Radiography , Sclerosis/diagnosis , Sclerosis/diagnostic imaging , Sclerosis/microbiology , Sclerosis/veterinary , Spondylitis/diagnosis , Spondylitis/diagnostic imaging , Spondylitis/microbiology , Thoracic Vertebrae/diagnostic imaging , Thoracic Vertebrae/pathologyABSTRACT
Adrenal neoplasia is a common problem in middle-aged to older ferrets. Male ferrets may present for stranguria and dysuria due to prostatic/paraurethral tissue enlargement secondary to elevation in androgens produced by the neoplastic tissue. Progressive urethral compression followed by complete urinary obstruction can result. Urinary obstruction can persist for days following surgery requiring urinary diversion. Four ferrets presenting with signs consistent with urinary obstruction secondary to adrenal disease were immediately treated with urethral catheterization or cystocentesis followed by adrenalectomy and temporary tube cystostomy. The tube cystostomy placement and use were associated with minimal complications and allowed recovery from surgery.